The incidence of type 2 diabetes mellitus (DM) has been increasing rapidly, and the disease has become a serious sociomedical problem. Many skin problems, such as xerosis, pruritus, skin infections and delayed wound healing, that might be related to chronic impairment of skin barrier function decrease the quality of life in patients with DM. However, the status of the permeability and antimicrobial barrier of the skin in DM remains unknown. This study aimed to elucidate skin barrier impairment in patients with type 2 DM and its pathomechanisms using classic animal models of type 2 DM. Functional studies of the skin barrier and an analysis of stratum corneum (SC) lipids were compared between patients with type 2 DM and age‐ and sex‐matched non‐diabetes controls. Also, functional studies on the skin barrier, epidermal lipid analyses, and electron microscopy and biomolecular studies were performed using type 2 DM animal models, db/db and ob/ob mice. Patients with type 2 DM presented with epidermal barrier impairments, including SC hydration, which was influenced by blood glucose control (HbA1c level). In the lipid analysis of SC, ceramides, fatty acids and cholesterol were significantly decreased in patients with type 2 DM compared with controls. Type 2 DM murine models presented with severe hyperglycaemia, impairment of skin barrier homeostasis, decreases in epidermal proliferation and epidermal lipid synthesis, decreases in lamellar body (LB) and epidermal antimicrobial peptides (AMPs), an increase in receptors for advanced glycation end‐product (AGE) in the epidermis and an increase in serum AGE. Impairment of the skin barrier was observed in type 2 DM, which results in part from a decrease in epidermal proliferation. Serum AGE and its epidermal receptors were increased in type 2 diabetic mice which display impaired skin barrier parameters such as epidermal lipid synthesis, LB production, epidermal AMP and SC lipids.

No abstract

No abstract

The synthesis and photovoltaic characteristics of new organic semiconductors, [bisDMFA-Th]-BT-HxTh 3 (1), [bisDMFA-Th]-MonoF-BT-HxTh 3 (2), and [bisDMFATh]-DiF-BT-HxTh 3 (3), are reported. These semiconductors have an unsymmetrical donor A−acceptor−donor B (D A -A-D B ) framework composed of a benzothiadiazole (BT;fluorinated or unfluorinated) acceptor between two different donors, bisDMFA and terthiophene. We have demonstrated that these compounds are suitable for use in p-type organic semiconductors for high efficiency solution-processed small molecule organic solar cells (SMOSCs), for which we achieved a remarkable power conversion efficiency of 4.24% with a maximum V oc of 0.89 V. The fluorine substitution on BT decreased its HOMO level and increased hole mobilities of [bisDMFA-Th]-BT-HxTh 3 derivatives, leading to an increased V oc in the SMOSCs and improved hole carrier transport properties of the material. In addition, we determined that the insertion of a TiO x functional layer into a bulk heterojunction (BHJ) solar cell significantly reduced the interfacial resistance between the photoactive film and metal electrode, resulting in an increased photocurrent with facile electron transfer between these two layers.

Alopecia areata (AA) affects anagen hair follicles, resulting in non-scarring hair loss. Since introduced by Huang et al., superficial cryotherapy has been accepted as a considerable primary therapeutic modality for AA. The aim of this study was to objectively clarify the therapeutic efficacy and safety of superficial hypothermic cryotherapy for treatment of AA. Medical records of 353 patients from 1993 to 2014 were retrospectively analyzed. According to the response to the superficial cryotherapy, patients were categorized into four groups: "marked", "partial", "poor" and "no recovery". The marked and partial recovery groups were considered as responders. The proportions of the responders among patient subgroups which were defined by various patients, disease, and treatment factors were compared. Of the patients, 60.9% were classified as responders after 3 months of superficial hypothermic cryotherapy. The proportion of the responders were higher when the treatment interval was 2 weeks or less and in the incipient disease stage, with statistical significance. No severe side-effects other than mild pain and pruritus were reported. In conclusion, superficial cryotherapy is an effective and safe therapeutic modality for AA. Especially when the treatment interval is 2 weeks or less and in the first occurrence of the disease, the therapeutic outcome is superior.